24 Results

People

  1. Maclachlan
    Maclachlan
  2. Usmani
    Usmani
  3. Lesokhin
    Lesokhin
  4. Korde
    Korde
  5. Hassoun
    Hassoun
  6. Mailankody
    Mailankody
  7. Shah
    Shah
  8. Tan
    Tan
  9. Landau
    Landau
  10. Chung
    Chung

Groups

  1. GME, Medicine (24)
  2. Graduate Medical Education (24)
  3. Center for Hematologic Malignancies (22)
  4. Department of Medicine (22)
  5. Hematologic Malignancies, Division of (22)
  6. Myeloma (22)
  7. Hematologic Malignancies Research (21)
  8. Sloan Kettering Institute Postdocs (21)
  9. Survivorship Research (21)
  10. CTCR Scholars (19)
  1. "Clinical Lymphoma, Myeloma and Leukemia"
  2. "Kylee Maclachlan"
Formats
  1. Meeting Abstract (24)
Groups
  1. GME, Medicine (24)
  2. Graduate Medical Education (24)
  3. Center for Hematologic Malignancies (22)
  4. Department of Medicine (22)
  5. Hematologic Malignancies, Division of (22)
  6. Myeloma (22)

More Groups

People
  1. Kylee Maclachlan (24)
  2. Saad Usmani (23)
  3. Alexander Lesokhin (21)
  4. Malin Hultcrantz (20)
  5. Neha Korde (20)
  6. Carlyn Rose Tan (19)

More People

Years
  1. 2023 (16)
  2. 2022 (7)
  3. 2021 (1)
Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (24)
Publishers
  1. Elsevier Inc. (24)

Results (24)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Genomic and transcriptomic landscape of hyper-APOBEC multiple myeloma
    Meeting Abstract

    Papadimitriou, M.; Ziccheddu, B.; Youssfi, A.; Tauro, M.; Meads, M.; Maclachlan, K.; Usmani, S.; Poos, A.; Raab, M.; Weinhold, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology
    Meeting Abstract

    Maclachlan, K.; Blaney, P.; Gagler, D.; Boyle, E.; Diamond, B.; Shah, U.; Korde, N.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Individualized risk in newly diagnosed multiple myeloma
    Meeting Abstract

    Maura, F.; Rajanna, A.; Ziccheddu, B.; Derkach, A.; Poos, A.; Maclachlan, K.; Boyle, E.; Hultcrantz, M.; Silva, A.; Jackson, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save